Journal
BIOMARKERS IN MEDICINE
Volume 12, Issue 7, Pages 799-812Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2017-0433
Keywords
A beta; Alzheimer's disease; amyloid-beta; biomarkers; blood-based biomarkers; cerebrospinal fluid; dementia; positron emission tomography
Categories
Funding
- Butterfield Trust (via Rosetree Trust UK)
- Wallenberg Foundation
- Knut och Alice Wallenberg Foundation (the Wallenberg Centre for Molecular and Translational Medicine)
- Swedish Research Council
- Swedish Alzheimer Foundation
- Research Centre for Mental Health and Biomedical Research Unit for Dementia
- Brain Biomarker Solutions in Gothenburg AB
- GU Ventures-based platform company at the University of Gothenburg
- TEVA
Ask authors/readers for more resources
At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-beta (A beta) into oligomers, fibrils and plaques. Effective monitoring of A beta deposition directly in patients is essential to assist anti-A beta therapeutics in target engagement and participant selection. In the advent of approved anti-A beta therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established A beta biomarkers are widely utilized: A beta-binding ligands for positron emission tomography and immunoassays to measure A beta 42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for A beta pathology. Furthermore, we will explore the current application of blood-based markers to assess A beta pathology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available